Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an update.
Botanix Pharmaceuticals has secured a debt facility of approximately A$48 million from Kreos Capital to support the commercialization of its lead product, Sofdra™, and explore platform expansion opportunities. This financial arrangement, alongside a recent capital raise and existing cash reserves, positions Botanix to accelerate Sofdra™ sales and pursue strategic growth initiatives, enhancing its market presence and operational capabilities.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in developing treatments for skin conditions. Its primary product, Sofdra™, is a topical gel approved by the FDA for treating primary axillary hyperhidrosis, a condition characterized by excessive underarm sweating. Botanix focuses on providing novel and effective solutions for dermatological issues.
Average Trading Volume: 10,877,322
Technical Sentiment Signal: Hold
Current Market Cap: A$647.1M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue